专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120289467A1 Compositions and Methods Utilizing Fibrin Beta Chain Fragments 有权
标题翻译：使用纤维蛋白β链片段的组合物和方法
公开(公告)号：US20120289467A1
公开(公告)日：2012-11-15
申请号：US12678122
申请日：2008-09-17
申请人： Leonid Medved , Li Zhang , Sergiy Yakovlev
发明人： Leonid Medved , Li Zhang , Sergiy Yakovlev
IPC分类号： C07K14/75 , A61P9/10 , A61K38/36
CPC分类号： C07K14/75
摘要： A composition including a peptide sequence of the formula βX1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type β15-42 monomer sequence per se, and wherein the peptide sequence is other than (β15-66)2 dimer having two chains with each chain limited to wild type amino acids β15-65 and each chain further including a non-naturally occurring Gly at position 66 of each chain. Methods for treatment and pharmaceutical combinations may include a polypeptide agent such as Thymosin beta 4. In such methods and combinations, a dimer of the peptide sequence may include amino acids 15-66 of the fibrin beta chain.
摘要翻译：包含式＆bgr的肽序列X1-X2的组合物，所述肽序列对应于纤维蛋白原的Bbeta链的纤维蛋白β链片段的氨基酸序列，其中X1表示肽序列的N-末端， X2表示肽序列的C末端，其中肽序列包括X1和X2之间的额外氨基酸，其中肽序列可以含有非天然存在的氨基酸残基，其中肽序列不是野生型型单体序列本身，并且其中所述肽序列不同于具有每条链的每个链限定于野生型氨基酸（15-65）的每个链（＆amp; 15-66）2二聚体，并且每个链进一步包括每个链的位置66处的非天然存在的Gly。用于治疗和药物组合的方法可以包括多肽试剂例如胸腺素β4。在这些方法和组合中，肽序列的二聚体可以包括纤维蛋白β链的氨基酸15-66。

2. 发明授权

US08722623B2 Compositions and methods utilizing fibrin beta chain fragments 有权
标题翻译：使用纤维蛋白β链片段的组合物和方法
公开(公告)号：US08722623B2
公开(公告)日：2014-05-13
申请号：US12678122
申请日：2008-09-17
申请人： Leonid Medved , Li Zhang , Sergiy Yakovlev
发明人： Leonid Medved , Li Zhang , Sergiy Yakovlev
IPC分类号： A61K38/36 , A61P7/04 , C07K14/75 , C07K14/475
CPC分类号： C07K14/75
摘要： A composition including a peptide sequence of the formula βX1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type β15-42 monomer sequence per se, and wherein the peptide sequence is other than (β15-66)2 dimer having two chains with each chain limited to wild type amino acids β15-65 and each chain further including a non-naturally occurring Gly at position 66 of each chain. Methods for treatment and pharmaceutical combinations may include a polypeptide agent such as Thymosin beta 4. In such methods and combinations, a dimer of the peptide sequence may include amino acids 15-66 of the fibrin beta chain.
摘要翻译：包含式＆bgr的肽序列X1-X2的组合物，所述肽序列对应于纤维蛋白原的Bbeta链的纤维蛋白β链片段的氨基酸序列，其中X1表示肽序列的N-末端， X2表示肽序列的C末端，其中肽序列包括X1和X2之间的额外氨基酸，其中肽序列可以含有非天然存在的氨基酸残基，其中肽序列不是野生型型单体序列本身，并且其中所述肽序列不同于具有每条链的每个链限定于野生型氨基酸（15-65）的每个链（＆amp; 15-66）2二聚体，并且每个链进一步包括每个链的位置66处的非天然存在的Gly。用于治疗和药物组合的方法可以包括多肽试剂例如胸腺素β4。在这些方法和组合中，肽序列的二聚体可以包括纤维蛋白β链的氨基酸15-66。

3. 发明申请

US20190151415A1 COMPOSITIONS FOR INHIBITING FIBRIN-VLDL RECEPTOR-DEPENDENT INFLAMMATION AND METHODS OF TREATMENT 审中-公开
公开(公告)号：US20190151415A1
公开(公告)日：2019-05-23
申请号：US16306824
申请日：2017-06-02
申请人： Leonid V. Medved , Dudley Strickland , Sergiy Yakovlev
发明人： Leonid V. Medved , Dudley Strickland , Sergiy Yakovlev
IPC分类号： A61K38/17 , A61P37/06 , A61P9/10 , A61K38/36
摘要： The invention provides a method of treating inflammation, comprising administering to a subject in need thereof a therapeutically effective amount of an agent that inhibits binding of fibrin to Very Low Density Lipoprotein Receptor (VLDLR) or combination of this agent with agents inhibiting binding of fibrin to VE-cahherin (vascular endothelial cadherin).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式